BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$7.95 USD
-0.19 (-2.33%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $7.96 +0.01 (0.13%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BCRX 7.95 -0.19(-2.33%)
Will BCRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCRX
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
BCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth
Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?
Ensign Group Boosts U.S. Presence With Idaho and Texas Facility Buyouts
Other News for BCRX
BioCryst Pharmaceuticals Q2 2025 Earnings Preview
Earnings Outlook For BioCryst Pharma
BioCryst appoints Charlie Gayer to succeed Jon Stonehouse as CEO
BioCryst Pharmaceuticals Announces CEO Transition | BCRX stock news
BioCryst (BCRX) Announces Leadership Transition Plan